OptiNose, Inc. (OPTN)
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
$117.61M
Dr. Ramy A. Mahmoud M.D., M.P.H.
189.00
Yardley, PA
Oct 13, 2017
-2.17
$-0.36
2.79
3.94
-54.50%
-2.78
0.19
-2.65
1.55
3.59
-31.02%
53.43%
Similar stocks (15)
Neurocrine Biosciences, Inc.
NBIX
Intra-Cellular Therapies, Inc.
ITCI
Prestige Consumer Healthcare Inc.
PBH
Amphastar Pharmaceuticals, Inc.
AMPH
Dynavax Technologies Corporation
DVAX
ANI Pharmaceuticals, Inc.
ANIP
Collegium Pharmaceutical, Inc.
COLL
Phibro Animal Health Corporation
PAHC
Evolus, Inc.
EOLS
Ironwood Pharmaceuticals, Inc.
IRWD
Lifecore Biomedical, Inc.
LFCR
Silver Spike Investment Corp.
SSIC
Cumberland Pharmaceuticals Inc.
CPIX
Eagle Pharmaceuticals, Inc.
EGRX
Shuttle Pharmaceuticals Holdings, Inc.
SHPH
ETF Exposure (14)
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.359%
JPMorgan Short Duration Core Plus ETF
JSCP
0.1%
JPMorgan Core Plus Bond ETF
JCPB
0.02%
iShares Micro-Cap ETF
IWC
0.01322%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (15)
Neurocrine Biosciences, Inc.
NBIX
Intra-Cellular Therapies, Inc.
ITCI
Prestige Consumer Healthcare Inc.
PBH
Amphastar Pharmaceuticals, Inc.
AMPH
Dynavax Technologies Corporation
DVAX
ANI Pharmaceuticals, Inc.
ANIP
Collegium Pharmaceutical, Inc.
COLL
Phibro Animal Health Corporation
PAHC
Evolus, Inc.
EOLS
Ironwood Pharmaceuticals, Inc.
IRWD
Lifecore Biomedical, Inc.
LFCR
Silver Spike Investment Corp.
SSIC
Cumberland Pharmaceuticals Inc.
CPIX
Eagle Pharmaceuticals, Inc.
EGRX
Shuttle Pharmaceuticals Holdings, Inc.
SHPH
ETF Exposure (14)
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.359%
JPMorgan Short Duration Core Plus ETF
JSCP
0.1%
JPMorgan Core Plus Bond ETF
JCPB
0.02%
iShares Micro-Cap ETF
IWC
0.01322%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%